Download SARS and Lantigen B

To whom it may concerns
SWINE FLU and Lantigen B.
It is a common notion in immunology that the best immune-response are raised against
infectious agents. This is particularly true when bacteria are involved in the infection,
because of their capacity to induce the activation and maturation of immature dendritic
cells to mature antigen presenting – dendritic cells. This activation/maturation process is
strongly supported by the presence of specific bacterial structures (such as
lipopolysaccaride – LPS – and protidoglicans) recognized by the so-called Toll-Like
receptors (TLR) expressed on immature dendritic cells. Following this molecular
interaction, dendritic cells mature and secrete a number of cytokines and chemokines
deeply involved in the efficacy of antigen recognition and subsequent activation of the
adaptive (specific) arm of the immune-response.
Problems related to a poor capacity to recognize and eliminate infectious agents such as
viruses are sometimes related to the incapacity of the immune response to recognize the
foreign antigens and initiate an efficient specific immune-response. For this reason, the
combination of viral antigens and bacterial antigens (either used as adjuvant or used as
vaccine against bacterial disease) had resulted in a strong and largely distributed
activation of the specific immune-response in humans. This finding has been recently
strongly supported by a study in young humans, treated with BCG, measles and poliovirus
as vaccines. The control group, where BCG was absent, resulted in a weaker immuneresponse against the viral antigens.
The combination of Lantigen B, a natural bacteria-derived drug expressing both the
soluble and the particulate fraction of bacterial antigens and viral vaccine should be
strongly supported not only in patients with a natural weak immune-response, but also in
developing countries where both the emerging infections and the style of life may result in
a higher risk of epidemic infections. Along this line, the capacity of Lantigen B to evoke a
specific immune-response as well as the capacity of inducing the maturation of dendritic
cells, should be used also in clinics when a novel infectious agents is spreading in the
country. The induction of maturation of Dendritic cells allows a stronger and more efficient
presentation of antigens not only related to the Lantigen B, but also to any other infectious
agent present in the country and potentially pathogenic. On these bases, I strongly
suggest the use of bacterial-derived drugs (such as Lantigen B) as both specific and nonspecific immunostimulants and adjuvants in patients belonging to cohorts or groups
potentially prone to the infection mediated by novel infectious agents.
Prof. G. MELIOLI
Analysis Laboratory
Hospital Unit
Scientific Institute “Giannina Gaslini”
Genoa/Italy